Streetbeat News

SYRE

Spyre Therapeutics, Inc.

https://www.spyre.com

Industry

Biotechnology

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Spyre Therapeutics (NASDAQ:SYRE) reported a Q2 EPS loss of $(0.86), beating the analyst estimate of $(0.95) by 9.47%. This represents a significant improvement from the $(41.50) loss per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:19 pm

Evercore ISI Group has initiated coverage on Spyre Therapeutics (NASDAQ:SYRE) with an Outperform rating, as announced by analyst Umer Raffat.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 2:33 pm

Spyre Therapeutics has started dosing healthy volunteers in its first clinical trial of SPY001 for Inflammatory Bowel Disease. Interim pharmacokinetic and safety data are expected by the end of 2024. SPY002 is set to begin first-in-human studies in the second half of 2024. All three next-generation antibodies are on track to be in the clinic within 12 months.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:33 am

Paragon Therapeutics has announced a license agreement with Spyre Therapeutics, granting Spyre exclusive rights to certain antibodies and products targeting α4ß7 integrin and TL1A. Paragon will receive up to $22 million in milestone payments and royalties from Spyre.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:57 am

Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $35 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 1:45 pm

BTIG analyst Julian Harrison has maintained a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $32 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 2:54 pm

Spyre Therapeutics (NASDAQ:SYRE) reported a Q1 2024 GAAP EPS loss of $(1.20), missing the consensus estimate of $(1.17) by 2.56%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:52 pm

Baird analyst Colleen Kusy initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with an Outperform rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 9:06 am

Stifel analyst Alex Thompson has reiterated a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $36 to $54, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:18 pm

Stifel analyst Alex Thompson has maintained a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $36 to $54.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 10:10 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.